Table 2. HRs of overall, 0–3, 3–12 and 12–24 months corrected LTFU by CD4 count at ART initiation^*.

	Overall (0–24 months) n=17 038	0–3 months n=17 038	3–12 months n=15 470	12–24 months n=12 728
Crude HR (cells/μL)
<50	1.13 (0.98 to 1.30)	1.10 (0.81 to 1.49)	1.34 (1.07 to 1.68)	0.95 (0.75 to 1.20)
50–99	1.01 (0.88 to 1.17)	1.14 (0.85 to 1.54)	1.05 (0.83 to 1.33)	0.92 (0.73 to 1.15)
100–149	1.01 (0.88 to 1.17)	0.66 (0.47 to 0.94)	1.14 (0.92 to 1.43)	1.08 (0.87 to 1.33)
150–199	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
200–249	0.95 (0.82 to 1.11)	0.84 (0.60 to 1.18)	1.03 (0.81 to 1.32)	0.94 (0.74 to 1.19)
250–299	1.38 (1.11 to 1.70)	1.56 (1.01 to 2.39)	1.39 (0.98 to 1.96)	1.27 (0.89 to 1.81)
≥300	1.62 (1.25 to 1.95)	1.95 (1.35 to 2.81)	1.70 (1.27 to 2.27)	1.34 (0.97 to 1.87)
Adjusted†—aHR (cells/μL)
<50	1.08 (0.94 to 1.24)	1.07 (0.79 to 1.45)	1.30 (1.04 to 1.63)	0.89 (0.70 to 1.12)
50–99	0.98 (0.85 to 1.13)	1.12 (0.83 to 1.52)	1.02 (0.81 to 1.29)	0.88 (0.70 to 1.11)
100–149	1.00 (0.87 to 1.14)	0.66 (0.47 to 0.93)	1.12 (0.90 to 1.40)	1.06 (0.85 to 1.30)
150–199	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
200–249	0.89 (0.77 to 1.04)	0.80 (0.57 to 1.12)	0.95 (74 to 1.22)	0.90 (0.71 to 1.15)
250–299	1.18 (0.95 to 1.46)	1.40 (0.90 to 2.16)	1.14 (0.80 to 1.62)	1.12 (0.89 to 1.60)
≥300	1.35 (1.12 to 1.63)	1.68 (1.15 to 2.45)	1.35 (1.00 to 1.81)	1.17 (0.84 to 1.64)

^*All estimates are stratified by cohort.

^†Adjusted for year of ART initiation, gender, age, programme size and rate of expansion.

ART, antiretroviral therapy; LTFU, loss to follow-up.